Cargando…

Pulmonary complications in hematopoietic SCT: a prospective study

Pulmonary complications are common and often lethal in hematopoietic SCT recipients. The objective of this prospective interventional study was to evaluate the etiology, diagnostic procedures, risk factors and outcome of pulmonary complications in a cohort of hematopoietic SCT recipients followed up...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucena, C M, Torres, A, Rovira, M, Marcos, M A, de la Bellacasa, J P, Sánchez, M, Domingo, R, Gabarrus, A, Mensa, J, Agustí, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094728/
https://www.ncbi.nlm.nih.gov/pubmed/25046219
http://dx.doi.org/10.1038/bmt.2014.151
_version_ 1783510529754529792
author Lucena, C M
Torres, A
Rovira, M
Marcos, M A
de la Bellacasa, J P
Sánchez, M
Domingo, R
Gabarrus, A
Mensa, J
Agustí, C
author_facet Lucena, C M
Torres, A
Rovira, M
Marcos, M A
de la Bellacasa, J P
Sánchez, M
Domingo, R
Gabarrus, A
Mensa, J
Agustí, C
author_sort Lucena, C M
collection PubMed
description Pulmonary complications are common and often lethal in hematopoietic SCT recipients. The objective of this prospective interventional study was to evaluate the etiology, diagnostic procedures, risk factors and outcome of pulmonary complications in a cohort of hematopoietic SCT recipients followed up for 1 year. For patients suffering from a pulmonary complication, a diagnostic algorithm that included non-invasive and bronchoscopic procedures was performed. We identified 73 pulmonary complications in 169 patients: 50 (68%) were pneumonias; 21 (29%) were non-infectious complications and 2 (3%) were undiagnosed. Viruses (particularly Rhinovirus) and bacteria (particularly P. aeruginosa) (28 and 26%, respectively) were the most common causes of pneumonia. A specific diagnosis was obtained in 83% of the cases. A non-invasive test gave a specific diagnosis in 59% of the episodes. The diagnostic yield of bronchoscopy was 67 and 78% in pulmonary infections. Early bronchoscopy (⩽5 days) had higher diagnostic yield than late bronchoscopy (78 vs 23%; P=0.02) for pulmonary infections. Overall mortality was 22 and 32% of all fatalities were due to pulmonary complications. Pulmonary complications are common and constitute an independent risk factor for mortality, stressing the importance of an appropriate clinical management. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/bmt.2014.151) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7094728
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70947282020-03-26 Pulmonary complications in hematopoietic SCT: a prospective study Lucena, C M Torres, A Rovira, M Marcos, M A de la Bellacasa, J P Sánchez, M Domingo, R Gabarrus, A Mensa, J Agustí, C Bone Marrow Transplant Article Pulmonary complications are common and often lethal in hematopoietic SCT recipients. The objective of this prospective interventional study was to evaluate the etiology, diagnostic procedures, risk factors and outcome of pulmonary complications in a cohort of hematopoietic SCT recipients followed up for 1 year. For patients suffering from a pulmonary complication, a diagnostic algorithm that included non-invasive and bronchoscopic procedures was performed. We identified 73 pulmonary complications in 169 patients: 50 (68%) were pneumonias; 21 (29%) were non-infectious complications and 2 (3%) were undiagnosed. Viruses (particularly Rhinovirus) and bacteria (particularly P. aeruginosa) (28 and 26%, respectively) were the most common causes of pneumonia. A specific diagnosis was obtained in 83% of the cases. A non-invasive test gave a specific diagnosis in 59% of the episodes. The diagnostic yield of bronchoscopy was 67 and 78% in pulmonary infections. Early bronchoscopy (⩽5 days) had higher diagnostic yield than late bronchoscopy (78 vs 23%; P=0.02) for pulmonary infections. Overall mortality was 22 and 32% of all fatalities were due to pulmonary complications. Pulmonary complications are common and constitute an independent risk factor for mortality, stressing the importance of an appropriate clinical management. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/bmt.2014.151) contains supplementary material, which is available to authorized users. Nature Publishing Group UK 2014-07-21 2014 /pmc/articles/PMC7094728/ /pubmed/25046219 http://dx.doi.org/10.1038/bmt.2014.151 Text en © Macmillan Publishers Limited 2014 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Lucena, C M
Torres, A
Rovira, M
Marcos, M A
de la Bellacasa, J P
Sánchez, M
Domingo, R
Gabarrus, A
Mensa, J
Agustí, C
Pulmonary complications in hematopoietic SCT: a prospective study
title Pulmonary complications in hematopoietic SCT: a prospective study
title_full Pulmonary complications in hematopoietic SCT: a prospective study
title_fullStr Pulmonary complications in hematopoietic SCT: a prospective study
title_full_unstemmed Pulmonary complications in hematopoietic SCT: a prospective study
title_short Pulmonary complications in hematopoietic SCT: a prospective study
title_sort pulmonary complications in hematopoietic sct: a prospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094728/
https://www.ncbi.nlm.nih.gov/pubmed/25046219
http://dx.doi.org/10.1038/bmt.2014.151
work_keys_str_mv AT lucenacm pulmonarycomplicationsinhematopoieticsctaprospectivestudy
AT torresa pulmonarycomplicationsinhematopoieticsctaprospectivestudy
AT roviram pulmonarycomplicationsinhematopoieticsctaprospectivestudy
AT marcosma pulmonarycomplicationsinhematopoieticsctaprospectivestudy
AT delabellacasajp pulmonarycomplicationsinhematopoieticsctaprospectivestudy
AT sanchezm pulmonarycomplicationsinhematopoieticsctaprospectivestudy
AT domingor pulmonarycomplicationsinhematopoieticsctaprospectivestudy
AT gabarrusa pulmonarycomplicationsinhematopoieticsctaprospectivestudy
AT mensaj pulmonarycomplicationsinhematopoieticsctaprospectivestudy
AT agustic pulmonarycomplicationsinhematopoieticsctaprospectivestudy